Short and long-term effectiveness and safety of vedolizumab in inflammatory bowel disease: results from the ENEIDA registry

Inflammatory Bowel Disease

Effectiveness and Safety of the Sequential Use of a Second and Third Anti-TNF Agent in Patients With Inflammatory Bowel Disease: Results From the Eneida Registry

Inflamm Bowel Dis.

Casanova MJ, Chaparro M, Mínguez M, Ricart E, Taxonera C, García-López S, Guardiola J, López-San Román A, Iglesias E, Beltrán B, Sicilia B, Vera MI, Hinojosa J, Riestra S, Domènech E, Calvet X, Pérez-Calle JL, Martín-Arranz MD, Aldeguer X, Rivero M, Monfort D, Barrio J, Esteve M, Márquez L, Lorente R, García-Planella E, de Castro L, Bermejo F, Merino O, Rodríguez-Pérez A, Martínez-Montiel P, Van Domselaar M, Alcaín G, Domínguez-Cajal M, Muñoz C, Gomollón F, Fernández-Salazar L, García-Sepulcre MF, Rodríguez-Lago I, Gutiérrez A, Argüelles-Arias F, Rodriguez C, Rodríguez GE, Bujanda L, Llaó J, Varela P, Ramos L, Huguet JM, Almela P, Romero P, Navarro-Llavat M, Abad Á, Ramírez-de la Piscina P, Lucendo AJ, Sesé E, Madrigal RE, Charro M, García-Herola A, Pajares R, Khorrami S, Gisbert JP

doi: 10.1093/ibd/izz192.

Inflammatory Bowel Disease

Real world data on effectiveness, safety and therapeutic drug monitoring of vedolizumab in patients with inflammatory bowel disease. A single center cohort

Scand J Gastroenterol.

Buer LCT, Moum BA, Cvancarova M, Warren DJ, Bolstad N, Medhus AW, Høivik ML

doi: 10.1080/00365521.

Inflammatory Bowel Disease

Impact of Bariatric Surgery on the Long-term Disease Course of Inflammatory Bowel Disease

Inflamm Bowel Dis.

Neto MBB, Gregory MH, Ramos GP, Bazerbachi F, Bruining DH, Abu Dayyeh BK, Kushnir VM, Raffals LE, Ciorba MA, Loftus EV, Deepak P

doi: 10.1093/ibd/izz236.

Inflammatory Bowel Disease

Real-world effectiveness and safety of Vedolizumab for the treatment of Inflammatory Bowel Disease: The Scottish Vedolizumab Cohort

J Crohns Colitis.

Plevris N, Chuah CS, Allen RM, Arnott ID, Brennan PN, Chaudhary S, Churchhouse AMD, Din S, Donoghue E, Gaya DR, Groome M, Jafferbhoy HM, Jenkinson PW, Lam WL, Lyons M, Macdonald JC, MacMaster M, Mowat C, Naismith GD, Potts LF, Saffouri E, Seenan JP, Sengupta A, Shasi P, Sutherland DI, Todd JA, Veryan J, Watson AJM, Watts DA, Jones GR, Lees CW

doi: 10.1093/ecco-jcc/jjz042.

Inflammatory Bowel Disease

"Long-term efficacy and safety of Vedolizumab in Inflammatory Bowel Diseases patients: a real-life experience from a Tertiary Referral Center"

J Dig Dis.

Dragoni G, Bagnoli S, Le Grazie M, Campani C, Rogai F, Manetti N, Bensi C, Macri' G, Galli A, Milla M

doi: 10.1111/1751-2980.

Inflammatory Bowel Disease

Peripheral Blood Eosinophilia and Long-term Severity in Pediatric-Onset Inflammatory Bowel Disease

Inflamm Bowel Dis.

Prathapan KM, Ramos Rivers C, Anderson A, Koutroumpakis F, Koutroubakis IE, Babichenko D, Tan X, Tang G, Schwartz M, Proksell S, Johnston E, Hashash JG, Dunn M, Wilson A, Barrie A, Harrison J, Hartman D, Kim SC, Binion DG

doi: 10.1093/ibd/izz323.

Inflammatory Bowel Disease

Switching to a infliximab biosimilar: short-term results of clinical monitoring in patients with inflammatory bowel disease

Eur J Gastroenterol Hepatol.

Binkhorst L, Sobels A, Stuyt R, Westerman EM, West RL

doi: 10.1097/

Inflammatory Bowel Disease

Assessment of small bowel mucosal healing by video capsule endoscopy for the prediction of short-term and long-term risk of Crohn's disease flare: a prospective cohort study

Lancet Gastroenterol Hepatol.

Ben-Horin S, Lahat A, Amitai MM, Klang E, Yablecovitch D, Neuman S, Levhar N, Selinger L, Rozendorn N, Turner D, Chowers Y, Odes S, Schwartz D, Yanai H, Dotan I, Braun T, Haberman Y, Kopylov U, Eliakim R, Israeli IBD Research Nucleus (IIRN)

doi: 10.1016/S2468-1253(19)30088-3.

Inflammatory Bowel Disease

Effect of distance to specialist care for the diagnosis and disease outcome of inflammatory bowel disease in the Swiss inflammatory bowel disease cohort study

Therap Adv Gastroenterol.

Grob L, Bluemel S, Biedermann L, Fournier N, Rossel JB, Vavricka SR, Zeitz J, Rogler G, Stallmach A, Scharl M

doi: 10.1177/1756284819895217.

Related content

Effectiveness and Safety of the Sequential Use of a Second and Third Anti-TNF Agent in Patients With Inflammatory Bowel Disease: Results From the Eneida Registry

Real world data on effectiveness, safety and therapeutic drug monitoring of vedolizumab in patients with inflammatory bowel disease. A single center cohort

Impact of Bariatric Surgery on the Long-term Disease Course of Inflammatory Bowel Disease

Real-world effectiveness and safety of Vedolizumab for the treatment of Inflammatory Bowel Disease: The Scottish Vedolizumab Cohort

"Long-term efficacy and safety of Vedolizumab in Inflammatory Bowel Diseases patients: a real-life experience from a Tertiary Referral Center"

Peripheral Blood Eosinophilia and Long-term Severity in Pediatric-Onset Inflammatory Bowel Disease

Switching to a infliximab biosimilar: short-term results of clinical monitoring in patients with inflammatory bowel disease

Assessment of small bowel mucosal healing by video capsule endoscopy for the prediction of short-term and long-term risk of Crohn's disease flare: a prospective cohort study

Effect of distance to specialist care for the diagnosis and disease outcome of inflammatory bowel disease in the Swiss inflammatory bowel disease cohort study